{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:37:59Z","timestamp":1792636679903,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Salvage autologous hematopoietic cell transplantation (auto-HCT) may be used to treat relapse of plasma cell myeloma occurring after previous auto-HCT. When an insufficient number of hematopoietic stem cells have been stored from the initial harvest, remobilization is necessary. Here, we aimed to analyze the efficacy and safety of different doses of cytarabine (total 800 vs. 1600 vs. 2400 mg\/m2) for remobilization. Sixty-five patients, 55% male, with a median age at remobilization 63 years, were included. Remobilization was performed with cytarabine_800 in 7, cytarabine_1600 in 36, and cytarabine_2400 in 22 patients. Plerixafor rescue was used in 25% of patients receiving cytarabine_1600 and 27% of those receiving cytarabine_2400. Patients administered cytarabine_800 were not rescued with plerixafor. Remobilization was successful in 80% of patients (57% cytarabine_800; 86% cytarabine_1600; 77% cytarabine_2400; p = 0.199). The yield of collected CD34+ cells did not differ between the different cytarabine doses (p = 0.495). Patients receiving cytarabine_2400 were at the highest risk of developing severe cytopenias, requiring blood product support, or having blood-stream infections. One patient died of septic shock after cytarabine_2400. In summary, remobilization with cytarabine is feasible in most patients. All doses of cytarabine allow for successful remobilization. Cytarabine_2400 is associated with higher toxicity; therefore, lower doses (800 or 1600 mg\/m2) seem to be preferable.<\/jats:p>","DOI":"10.3390\/cancers16142588","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T13:12:57Z","timestamp":1721394777000},"page":"2588","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation\u2014A Multicenter Report by the Polish Myeloma Study Group"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-1750","authenticated-orcid":false,"given":"Anna","family":"Waszczuk-Gajda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Topczewska","sequence":"additional","affiliation":[{"name":"Faculty of Computer Science, Bialystok University of Technology, 15-351 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-7684","authenticated-orcid":false,"given":"Martyna","family":"Maciejewska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Dutka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szmigielska-Kap\u0142on","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-2000","authenticated-orcid":false,"given":"Mateusz","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-0872","authenticated-orcid":false,"given":"Magdalena","family":"Olszewska-Szopa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szeremet","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-0182","authenticated-orcid":false,"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kozio\u0142","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Ma\u0144ko","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"},{"name":"Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"},{"name":"Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Romejko-Jarosi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-7033","authenticated-orcid":false,"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"M\u0105dry","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Boguradzki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Kr\u00f3l","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilian","family":"Snarski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"},{"name":"Faculty of Medicine and Health Science, University of Zielona G\u00f3ra, 65-046 Zielona G\u00f3ra, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Haematology, Trinity College Dublin, St. James\u2019s Hospital, D08 NHY1 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Dwilewicz-Trojaczek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-8180","authenticated-orcid":false,"given":"Grzegorz W\u0142adys\u0142aw","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbmt.2012.11.013","article-title":"Autologous stem cell transplantation: An effective salvage therapy in multiple myeloma","volume":"19","author":"Lemieux","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: Impact on progression-free and overall survival","volume":"18","author":"Mikhael","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/bmt.2015.39","article-title":"Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT","volume":"50","author":"Grovdal","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2018-99-111203","article-title":"Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide\/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse","volume":"132","author":"Goldschmidt","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bbmt.2020.04.016","article-title":"Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT","volume":"26","author":"Laurent","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.bbmt.2016.01.016","article-title":"Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation\/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial","volume":"22","author":"Parrish","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/leu.2013.214","article-title":"Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: Low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia","volume":"28","author":"Papanikolaou","year":"2014","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bmt.2012.135","article-title":"Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT","volume":"48","author":"Khaled","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.2011.01605.x","article-title":"Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells","volume":"86","author":"Basak","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.12888","article-title":"Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE","volume":"99","author":"Baertsch","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jca.21885","article-title":"Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group","volume":"36","author":"Topczewska","year":"2021","journal-title":"J. Clin. Apher."},{"key":"ref_16","first-page":"475","article-title":"A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation","volume":"50","author":"Bittrich","year":"2023","journal-title":"Transfus. Med. Hemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41409-022-01592-y","article-title":"Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT","volume":"57","author":"Gras","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1080\/10428194.2021.1950712","article-title":"Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy\u2014A multicenter report by the Polish Myeloma Study Group","volume":"62","author":"Biecek","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5603\/AHP.2021.0003","article-title":"Current status and achievements of Polish haemato-oncology","volume":"52","author":"Giebel","year":"2021","journal-title":"Acta Haematol. Pol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.transci.2017.11.028","article-title":"Current status of art mobilization in Myeloma","volume":"56","author":"Sevindik","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2022, January 31). Version 5.0 Published: 27 November 2017, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/10428194.2016.1228926","article-title":"Treatment options for relapse after autograft in multiple myeloma\u2014Report from an EBMT educational meeting","volume":"58","author":"Garderet","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","article-title":"High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/14653240410005023","article-title":"Impaired PBPC collection in patients with myeloma after high-dose melphalan","volume":"6","author":"Jansen","year":"2004","journal-title":"Cytotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbmt.2018.09.023","article-title":"Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial","volume":"25","author":"Czerw","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bmt.2012.269","article-title":"Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers","volume":"48","author":"Giebel","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00277-015-2557-y","article-title":"Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: An analysis by the polish lymphoma research group","volume":"95","author":"Giebel","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12185-012-1135-5","article-title":"Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells","volume":"96","author":"Kruzel","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.leu.2403190","article-title":"Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H","volume":"18","author":"Montillo","year":"2004","journal-title":"Leukemia"},{"key":"ref_34","unstructured":"Snarski, E., Waszczuk-Gajda, A., G\u00f3rka, M., Maciejewska, M., Urbanowska, E., Lis, K., Feliksbrot-Bratosiewicz, M., Skwierawska, K., Heleniak, H., and Ziarkiewicz, M. (2019, January 24\u201327). Novel protocol for autologous HSCT in patients with high risk of complications: Ambulatory chemomobilization and transplantation of fresh hematopoietic stem cells with backup storage. Proceedings of the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Frankfurt, Germany."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2478\/ahp-2018-0027","article-title":"Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)","volume":"49","author":"Giebel","year":"2018","journal-title":"Acta Haematol. Pol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","article-title":"Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation","volume":"98","author":"Narayanasami","year":"2001","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: The predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26915","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2588\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:19:40Z","timestamp":1760109580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":39,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142588"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142588","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}